Can-Fite Biopharma Ltd each representing two (2) (CANF) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Can-Fite Biopharma Ltd each representing two (2) (NYSE: CANF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $1.62 (-2.41% 1D, market cap $4.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CANF ranks #935 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CANF carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XBIO (Xenetic Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -30.3%, cap $4.8M) and IMNN (Imunon Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M). Among the 5-stock peer group, CANF leads on earnings multiple (N/A) while XBIO leads on capital efficiency (-30.3% ROIC).
Per CANF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001536196), Can-Fite Biopharma Ltd each representing two (2) generated $405.0K in revenue (-39.9% YoY), -$9.8M in net income, and -$9.0M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.5 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CANF currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.19) and Max Pain ($1.70) forces dealer call-delta covering toward $13.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Can-Fite Biopharma Ltd each representing two (2) (CANF) dropped -2.41% to $1.62, trading at 2% of its 52-week range ($1.6 – $12.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. 02
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione TelethonRamat Gan, Israel, Nov.
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall surviva
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months and overall
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NE
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological an
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (T
The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Lt
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CANF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CANF. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Can-Fite Biopharma Ltd each representing two (2) (CANF) ranks #935 by composite RQD confidence (25/100, grade E) and #946 by equity capitalization ($4.9M). Within this direct 5-issuer industry benchmark cohort, CANF leads on earnings valuation at N/A trailing P/E, while XBIO leads on capital efficiency and profitability with -30.3% ROIC and — gross margin. PULM currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with CANF at 25/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CANF
ACTIVE
Can-Fite Biopharma Ltd each representing two (2) | E | 25/100 | — | — | -35.0% | -2.41% | $4.9M | Benchmark Subject |
| XBIO Xenetic Biosciences Inc. | E | 32/100 | — | — | -30.3% | -3.30% | $4.8M | /xbio-vs-canf → |
| IMNN Imunon Inc. | E | 31/100 | — | — | -35.0% | +9.24% | $5.1M | /imnn-vs-canf → |
| PULM Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -1.06% | $5.1M | /pulm-vs-canf → |
| AZTR Azitra Inc | E | 33/100 | — | — | -35.0% | +1.60% | $4.7M | /aztr-vs-canf → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Can-Fite Biopharma Ltd each representing two (2) (CANF) reported GAAP revenue of $405.0K (-39.9% vs. FY2024 revenue of $674.0K , and -45.5% cumulative change since FY2023) , GAAP net income of -$9.8M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-17.1% YoY). On the balance sheet, CANF closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $405.0K | -$9.8M | -$8.9M | -$9.0M | $9.5M | — |
| FY2024 (FY) | 2024-12-31 | $674.0K | -$7.9M | -$7.6M | -$7.6M | $9.1M | — |
| FY2023 (FY) | 2023-12-31 | $743.0K | -$7.6M | -$8.4M | -$8.4M | — | — |
As of 2026-11-03, Can-Fite Biopharma Ltd each representing two (2) (NYSE: CANF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $1.62 (-2.41% 1D, market cap $4.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CANF ranks #935 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CANF carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XBIO (Xenetic Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -30.3%, cap $4.8M) and IMNN (Imunon Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M). Among the 5-stock peer group, CANF leads on earnings multiple (N/A) while XBIO leads on capital efficiency (-30.3% ROIC).
Per CANF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001536196), Can-Fite Biopharma Ltd each representing two (2) generated $405.0K in revenue (-39.9% YoY), -$9.8M in net income, and -$9.0M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CANF last traded at $1.62 (-2.41% on volume of 22,439 shares), positioning the stock -26.03% below its 50-day simple moving average ($2.19) and -49.06% below its 200-day simple moving average ($3.18). Across its 52-week range of $1.60 to $12.40, CANF sits at the 0.2% percentile with a 14-day RSI of 26.5 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.45 to $1.79).
Why CANF Stock dropped -2.41% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CANF scores 26 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
For a prospective investor evaluating the stock today, the rating's message is that the company's economics (negative ROIC, zero FCF yield, negative margins) and its forensic scores both point toward risk. The upside case would have to rest on factors outside the reported fundamentals, and the source data contains no catalysts or analyst coverage to support one. The stock trades at $1.66 against a 52-week range of $1.6 to $12.4, a placement near the bottom of that range that reflects the deterioration the rating captures. The analysis is educational and does not constitute personalized financial advice.
Per the profile, Can-Fite Biopharma Ltd each representing two (2) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe the company's products, customers, or revenue model. It reports revenue of $0.4M for FY 2025, but no breakdown by product or customer is provided. Not available in source data for how the company makes money beyond these reported figures.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.4M | $-9.9M | $-9.8M | N/A | $-9.0M | $5.5M | N/A |
| FY 2024 | $0.7M | $-8.1M | $-7.9M | N/A | $-7.6M | $4.8M | N/A |
| FY 2023 | $0.7M | $-8.2M | $-7.6M | N/A | $-8.4M | N/A | N/A |
Per the SEC financials, the company has reported operating and net losses in each of the three periods provided, with FY 2025 revenue falling to $0.4M from $0.7M in FY 2024. Operating margin is -60% and net margin is -60% per the market data, and gross margin is 0%. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2 out of 9. Debt/Equity is 0.5 per the rating, while debt figures in the financials are N/A; cash of $5.5M at FY 2025 is the only balance-sheet line reported in the financials.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data.
Real-time company headlines, analyst actions, and sector developments for Can-Fite Biopharma Ltd each representing two (2) (CANF) • Click "Debate This Headline" to argue it in the Roar Pit below
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. 02
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione TelethonRamat Gan, Israel, Nov.
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall surviva
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patientsOne second-line patient achieved progression-free survival of 16.39 months and overall
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NE
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological an
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (T
Welcome to the CANF (Can-Fite Biopharma Ltd each representing two (2)) Roar Pit. Current RQD Composite is 26/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CANF, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Can-Fite Biopharma Ltd each representing two (2) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CANF, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.66 (52-wk range $1.60 - $12.40), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).